Two other areas where I've had concerns brought to me in my riding are, one, on the front of rare diseases, where the delays are perceived to be excessive; and two, on drugs relating to cancer. Is there any information you can share with us on how the CDR handles these two areas? Is there any concern that because of the smaller patient samples, CDR isn't currently best able to handle the approval or disapproval of drugs for rare diseases? And could you comment on the cancer front as well?
On April 25th, 2007. See this statement in context.